March 29, 2025

Kids with Down syndrome

Kids with Down syndrome can live 'abundant lives,' dad tells Fox News contributor


Fox News contributor Tom Shillue speaks to the dad of a child with Down syndrome on World Down Syndrome Day. Each year on March 21, World Down Syndrome Day (WDSD) marks a global day of awareness and education about the genetic condition.

The goal is to "help people understand and support those with Down syndrome better," according to the initiative's website. WDSD has been officially observed by the United Nations since 2012. On Friday, Fox News contributor Tom Shillue headed to Times Square in New York City to speak with New Yorkers about their awareness of WDSD. (See the video at the top of this article.)

Shillue spoke with Daniel Schreck, chairman of the Jérôme Lejeune Foundation, a global nonprofit focused on research and advocacy for people with genetic intellectual disabilities. Schreck also has a daughter with Down syndrome. When asked about common fears or misunderstandings about the condition, Schreck spoke of the perceived limitations. "I think the most important thing is that if you have Down syndrome, just like any other disability, you can live an abundant life and there's nothing to be afraid of," he said.

FAMILY OF CHILD WITH DOWN SYNDROME WENT FROM SHOCK TO GRATITUDE: ‘LOST THE AIR IN MY CHEST’

"Plus, people with Down's syndrome are the happiest people you've ever met. So there's nothing to be afraid of." The date of WDSD, the 21st day of the third month, was chosen to commemorate the triplication (trisomy) of the 21st chromosome, which is the cause of Down syndrome. Down syndrome is the most common chromosomal condition.

Down syndrome, trisomy 21, genetic disorder, intellectual disability, developmental delay, chromosomal abnormality, hypotonia, congenital heart disease, speech therapy, occupational therapy, early intervention, inclusive education, special needs, genetic counseling, physical therapy, facial features, prenatal screening, cognitive development, social inclusion, adaptive skills,

#DownSyndrome #Trisomy21 #GeneticDisorder #IntellectualDisability #DevelopmentalDelay #SpecialNeeds #InclusiveEducation #EarlyIntervention #SpeechTherapy #OccupationalTherapy #PhysicalTherapy #GeneticCounseling #SocialInclusion #CognitiveDevelopment #AdaptiveSkills #Hypotonia #CongenitalHeartDisease #PrenatalScreening #ChromosomalAbnormality #DownSyndromeAwareness


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 28, 2025

Coding Mutations to Meningomyelocele

The contribution of de novo coding mutations to meningomyelocele



Meningomyelocele (also known as spina bifida) is considered to be a genetically complex disease resulting from a failure of the neural tube to close. Individuals with meningomyelocele display neuromotor disability and frequent hydrocephalus, requiring ventricular shunting.

A few genes have been proposed to contribute to disease susceptibility, but beyond that it remains unexplained. We postulated that de novo mutations under purifying selection contribute to the risk of developing meningomyelocele. Here we recruited a cohort of 851 meningomyelocele trios who required shunting at birth and 732 control trios, and found that de novo likely gene disruption or damaging missense mutations occurred in approximately 22.3% of subjects, with 28% of such variants estimated to contribute to disease risk.

The 187 genes with damaging de novo mutations collectively define networks including actin cytoskeleton and microtubule-based processes, Netrin-1 signalling and chromatin-modifying enzymes. Gene validation demonstrated partial or complete loss of function, impaired signalling and defective closure of the neural tube in Xenopus embryos. Our results indicate that de novo mutations make key contributions to meningomyelocele risk, and highlight critical pathways required for neural tube closure in human embryogenesis.

Mutations, Genetic Variability, DNA Alterations, Genomic Instability, Somatic Mutations, Germline Mutations, Point Mutation, Frameshift Mutation, Missense Mutation, Nonsense Mutation, Silent Mutation, Deletion Mutation, Insertion Mutation, Duplication Mutation, Chromosomal Aberrations, Single Nucleotide Polymorphism (SNP), Mutagenesis, Oncogenic Mutations, Hereditary Mutations, Evolutionary Adaptation

#Mutations #Genetics #DNAChanges #GenomicInstability #SomaticMutation #GermlineMutation #PointMutation #FrameshiftMutation #MissenseMutation #NonsenseMutation #SilentMutation #DeletionMutation #InsertionMutation #DuplicationMutation #ChromosomalMutation #SNP #Mutagenesis #OncogenicMutation #HereditaryMutation #Evolution


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 27, 2025

Healthcare startups

Healthcare startups to see surge in M&A as funding dries up


Healthcare startups are set for increased mergers and acquisitions in 2025, driven by cash-strapped firms, declining revenue multiples, and investor caution, particularly in diagnostics and care delivery.

Healthcare startups are poised for increased mergers and acquisitions (M&A) in the current calendar year as revenue multiples decline and cash-strapped firms struggle in a tight funding market, according to early-stage healthcare-focused investment firm W Health Ventures.

The consolidation wave is expected to be most pronounced in diagnostics, where large pathology chains are likely to acquire smaller, hyperlocal labs and radiology centres to expand their geographic reach. Care delivery companies specialising in single fields such as IVF, eyecare, and oncology may also see exits, with promoters selling to private equity-backed platforms, said Namit Chugh, principal at W Health Ventures.

Investor caution has left many healthcare startups strapped for cash. Funding in the sector remained at nearly half of the average levels seen in 2021 and 2022, as backers waited for firms to achieve product-market fit before committing capital. As a result, 70% of early-stage healthcare startups have not raised a funding round since then, W Health Ventures said in a report on India’s healthcare ecosystem.

“A large number of healthcare startups with low cash reserves will become lucrative acquisition targets,” Chugh said. Late-stage, well-funded startups and global private equity firms are expected to drive most of the deal-making. With revenue multiples in private markets down by 60% from 2022 levels, acquisitions are now significantly more attractive for buyers.

Earlier this year, Wysa, an AI-powered mental health chatbot backed by W Health Ventures, merged with US-based April Health to integrate AI-driven mental health support into primary care, signaling a trend of strategic tie-ups.

Among different M&A models, acqui-hiring —where talent is acquired rather than just the business — could gain traction, offering startups an opportunity to expand service lines while securing high-quality, experienced teams. “We foresee more such transactions in 2025, including acquisitions via our portfolio companies,” W Health Ventures stated.

While consolidation accelerates in diagnostics and care delivery, quick-commerce healthcare ventures may struggle. Pharmacy quick-commerce startups face intensifying competition, which could lead to aggressive cash burn through speed and discount wars against local pharmacies. Inventory management challenges and regulatory compliance hurdles further compound the risks.

“By the end of 2025, we anticipate that at least a few q-commerce healthcare players will lose this race,” the report said. “The real question remains — aside from critical patients, does anyone really need medicines in ten minutes?”

Since 2021, W Health Ventures has been investing from its $100-million Fund I in startups such as BeatO, a personalised diabetes management platform; Mylo, a parenting community; AI-guided mental health firm Wysa; and Reveal Healthtech, which provides AI and engineering services to the healthcare industry. The firm is currently raising its second fund, targeting another $100 million.

Healthcare, medical research, patient care, public health, disease prevention, clinical trials, health technology, digital health, telemedicine, medical innovation, epidemiology, healthcare policy, mental health, precision medicine, biomedical science, health informatics, global health, personalized medicine, healthcare management, regenerative medicine,

#Healthcare #MedicalResearch #PatientCare #PublicHealth #DiseasePrevention #ClinicalTrials #HealthTech #DigitalHealth #Telemedicine #MedicalInnovation #Epidemiology #HealthcarePolicy #MentalHealth #PrecisionMedicine #BiomedicalScience #HealthInformatics #GlobalHealth #PersonalizedMedicine #HealthcareManagement #RegenerativeMedicine

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 26, 2025

Cell Division

How chromosomes shape up for cell division


Among the many marvels of life is the cell’s ability to divide and thus enable organisms to grow and renew themselves. For this, the cell must duplicate its DNA – its genome – and segregate it equally into two new daughter cells. To prepare the 46 chromosomes of a human cell for transport to the daughter cells during cell division, each chromosome forms a compact X-shaped structure with two rod-like copies. How the cell achieves this feat remains largely unknown.

Now, for the first time, EMBL scientists have directly observed this process in high resolution under the microscope using a new chromatin tracing method. The new study shows that the long DNA molecules of each chromosome form a series of overlapping loops during cell division that repel each other. As a result of this repulsion, the DNA loops then stack up to form rod-shaped chromosomes.

Tracing chromosomal DNA in high resolution


Scientists have long hypothesised the importance of DNA loops in building and maintaining chromosomal structure. First identified in the 1990s, condensins are large protein complexes that bind DNA during cell division and extrude it to create loops of varying sizes. Previous studies from EMBL have shed light on the structural mechanics of this process and their essential role in packing chromosomes into forms that can be easily moved between cells.

In fact, mutations in condensin structure can result in severe chromosome segregation defects and lead to cell death, cancer formation, or rare developmental disorders called ‘condensinopathies'.

“However, observing how this looping process occurs on the cellular scale and contributes to chromosome structure is challenging,” said Andreas Brunner, postdoc in EMBL Heidelberg's Ellenberg Group and a lead author of the new paper. “This is because methods for visualising DNA with high resolution are usually chemically harsh and require high temperatures, which together disrupt the native structure of DNA.”

Kai Beckwith – former postdoc in the Ellenberg Group and currently an associate professor at the Norwegian University of Science and Technology (NTNU) – set out to solve this problem. Beckwith and colleagues used a method to gently remove one strand of DNA in cells at various stages of cell division, keeping the chromosome structure intact. They could then use targeted sets of DNA-binding labels to observe the nanoscale organisation of this uncovered DNA strand. This technique, called LoopTrace, helped the researchers directly observe DNA in dividing cells as it progressively formed loops and folds.

“Andreas and I were now able to visualise the structure of chromosomes as they started to change shape,” said Beckwith. “This was crucial for understanding how the DNA was folded by the condensin complexes.”

Loops within loops


From their data, the scientists realised that during cell division, DNA forms loops in two stages. First, it forms stable large loops, which then subdivide into smaller, short-lived nested loops, increasing the compaction at each stage. Two types of condensin protein complexes enable this process.

To understand how this looping eventually gives rise to rod-shaped chromosomes, the researchers built a computational model based on two simple assumptions. First, as observed, DNA forms overlapping loops – first large and then small – across its length with the help of Condensins. Second, these loops repel each other due to their structure and the chemistry of DNA. When the scientists fed these two assumptions into their model, they found that this was sufficient to give rise to a rod-shaped chromosome structure.

“We realised that these condensin-driven loops are much larger than previously thought, and that it was very important that the large loops overlap to a significant extent”, said Beckwith. “Only these features allowed us to recapitulate the native structure of mitotic chromosomes in our model and understand how they can be segregated during cell division.”

In the future, the researchers plan to study this process in more detail, especially to understand how additional factors, such as molecular regulators, affect this compaction process. In 2024, Jan Ellenberg and his team received funding of €3.1 million as an ERC Advanced Grant, to study the folding principles of chromosomes during and following cell division.

“Our newest paper published in the scientific journal Cell marks a milestone in our understanding of how the cell is able to pack chromosomes for their accurate segregation into daughter cells,” said Jan Ellenberg, Senior Scientist at EMBL Heidelberg. “It will be the basis to understand the molecular mechanism of rescaling the genome for faithful inheritance and thus rationally predict how errors in this process that underlie human disease could be prevented in the future.”

In the meantime, a second study from the Ellenberg Team, led by Andreas Brunner and recently published in the Journal of Cell Biology, shows that the nested loop mechanism is fundamental to the biology of cells, and continues during the cell’s growth phase with another family of DNA loop forming protein complexes, called cohesins.

“We were surprised to find that the same core principle of sequential and hierarchical DNA loop formation is used to either tightly pack chromosomes during division into safely movable entities, or to unpack them afterwards to read out the information they contain,” said Ellenberg. “In the end, small, but key mechanistic differences, such as the non-overlapping nature of cohesin-driven loops compared to the strongly overlapping condensin-driven loops might be sufficient to explain the vast differences that we see in the shape the genome takes in interphase and mitosis under the microscope.”

Cell cycle, mitosis, meiosis, cytokinesis, chromatin, chromosome, centromere, spindle fibers, metaphase, anaphase, telophase, prophase, interphase, cell growth, DNA replication, sister chromatids, mitotic spindle, cell differentiation, genetic material, cell regulation

#CellDivision, #Mitosis, #Meiosis, #Cytokinesis, #Chromosome, #DNAReplication, #Genetics, #SpindleFibers, #Interphase, #Prophase, #Metaphase, #Anaphase, #Telophase, #CellCycle, #SisterChromatids, #MitoticSpindle, #CellGrowth, #GeneticMaterial, #CellBiology, #CellRegulation



International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 24, 2025

Genomics-Based Cancer Care

Delivering genomics-based cancer care for every community



Genomics has the power to transform cancer care, but only if it is implemented equitably and inclusively.

Australia has the world’s best cancer outcomes, but certain populations — including Aboriginal and Torres Strait Islander people, those living in rural and remote areas, culturally and linguistically diverse groups, and people with rare cancers — do not share this experience and have limited access to cutting-edge technologies. Addressing these disparities requires a multifaceted approach.

Recognising the critical importance of genomics in cancer care, the Australian Government launched the National Framework for Genomics in Cancer Control in February 2025 as a key action of the Australian Cancer Plan. The vision of this framework is clear: to integrate cancer genomics into routine clinical practice as the standard of care while ensuring accessibility, cultural safety and equity across the cancer care continuum. Together with the upcoming launch of Genomics Australia, we have a significant opportunity to align efforts and accelerate the integration of genomics in cancer care.

Last month, the Australian Government announced the establishment of a $3 million Cancer Genomics Clinical Trials Fund to drive advancements in genomic medicine and ensure equitable access to cancer clinical trials incorporating genomics. This new fund is a significant first step in implementing the framework and addressing key objectives for genomics-informed diagnosis, treatment, clinical trials, research and data.

The role of genomics in cancer care


Cancer is fundamentally a disease of the genome, involving mutations in DNA that can lead to uncontrolled cell growth. With advances in technology, we can identify genetic predispositions to cancer, enabling early intervention and personalised risk-reduction strategies. Genomic testing can also help determine the most effective, least toxic treatment plans, improving patient outcomes and quality of life.

The need for genomic literacy in cancer care


While the rapid advancement of genomics offers exciting possibilities, it also presents challenges, including the need for improved genomics literacy among both health care professionals and the broader public.

The volume of available information on genomics is expanding rapidly. It is crucial that patients can access accurate, reliable and evidence-based information and that medical professionals remain a trusted source for genomics guidance. This includes an understanding of the germline and somatic testing, the role of cascade testing, and the types of genomic testing, including whole genome sequencing, panel testing and tumour mutational burden.

To support clinicians in navigating these complexities, resources such as the eviQ referral guidelines for cancer genetics assessment are essential. By equipping health professionals with practical tools, we can improve personalised prevention, risk-reducing strategies, early detection and personalised treatment plans, ultimately leading to better patient outcomes.

Addressing equity: ensuring genomics benefits all Australians


Equity in cancer care is a fundamental measure of success under the framework. Without intentional efforts to improve access, there is a risk that genomic advancements will exacerbate existing health care inequities.

Ensuring culturally safe genomics-guided cancer care is a priority. This requires ongoing consultation and collaboration with Aboriginal and Torres Strait Islander communities who have higher cancer mortality rates and face barriers in accessing genomics-informed care.

In 2024, Cancer Australia conducted in-person workshops with Aboriginal and Torres Strait Islander community members, cancer patients, health care providers and community-controlled health services. These consultations reinforced the importance of self-determination, culture, capacity building, and access in shaping the future of cancer genomics care.

Moving forward: what needs to happen next?


The launch of the framework is just the beginning. Successful implementation requires a coordinated effort from the entire health care sector, including governments, researchers, health care providers, and advocacy groups.

Cancer Australia has identified four key priorities for implementation:


Integration into routine clinical practice


  • Establishing genomics as a standard component of cancer care to enable personalised cancer prevention and early detection and to guide treatment decisions.
  • Ensuring evidence-based genomic testing is available and accessible to patients regardless of geographic location or socio-economic status.
  • Promoting translational research and enabling timely access to genomics-informed cancer treatments through Health Technology Assessment processes and clinical trials.

Public awareness and workforce education and training


  • Enhancing genomics literacy among all health care professionals to ensure clinicians are confident in using genomics to guide cancer prevention and treatment.
  • Developing community awareness campaigns about cancer genomics and co-designing resources with priority populations and consumers.
  • Driving system level changes relating to cultural safety, with education for health providers that acknowledges the complex history of genomics for Aboriginal and Torres Strait Islander people.

Data and research

  • Strengthening data-sharing capabilities to maximise the benefits of genomics research and improve real-world applications.
  • Ensuring cancer genomic research and data are representative of population diversity, underpinned by Indigenous data sovereignty principles.

Equity and cultural safety

  • Developing tools for the specialist cancer workforce and primary care, including Aboriginal Community Controlled Health Services, to support shared decision making with patients about the use of genomics in cancer care.
  • Providing Aboriginal and Torres Strait Islander people and other priority populations with holistic navigation support and wrap-around personalised genomic cancer care.

Conclusion


Genomics has the power to transform cancer care, but only if it is implemented equitably and inclusively. The National Framework for Genomics in Cancer Control provides a roadmap for ensuring all Australians, regardless of background or location, can benefit from the latest advancements in personalised cancer care. However, achieving this vision requires commitment from the entire health care sector. Cancer Australia is committed to leading this charge, ensuring that genomics serves as a tool for better outcomes, improved patient experiences, and a more equitable cancer care for all Australians.

Genomics, DNA sequencing, genetic variation, gene expression, epigenetics, CRISPR, genome editing, bioinformatics, personalized medicine, transcriptomics, proteomics, metagenomics, population genetics, evolutionary genetics, functional genomics, structural genomics, synthetic biology, molecular diagnostics, gene therapy, pharmacogenomics,

#Genomics #DNASequencing #GeneticVariation #GeneExpression #Epigenetics #CRISPR #GenomeEditing #Bioinformatics #PersonalizedMedicine #Transcriptomics #Proteomics #Metagenomics #PopulationGenetics #EvolutionaryGenetics #FunctionalGenomics #StructuralGenomics #SyntheticBiology #MolecularDiagnostics #GeneTherapy #Pharmacogenomics


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 22, 2025

Genes is transforming Healthcare

Genomics: how unlocking our genes is transforming healthcare


Genomics is revolutionising modern medicine. From improving cancer treatments to predicting diseases using genetic information, here are four ways our health is benefitting from genomics. Genomics has fundamentally changed how we understand health and disease. It has made incredible advances in medicine possible, allowing us to treat diseases at a genetic level and offering more personalised treatments.

This progress has not come without challenges. For example, many questions and concerns have emerged around the ethical, legal and societal contexts of genomics research. These must be openly discussed and researched so that, ultimately, everyone can feel the positive impacts of genomics research on their health.

As genomics research improves to meaningfully include everyone everywhere, we are likely to see more breakthroughs that will have implications for health. But what impact has genomics made on health so far?

What is genomics and the Human Genome Project?


Genomics is the study of the structure and function of genomes, which is the entire set of DNA in an organism. It looks at how genes interact with each other and the environment.

Genomics helps us understand which genes are linked to physical traits, but this is not always easy. Many parts of our DNA don't seem to do anything obvious, and characteristics can be influenced by many different genes. To better understand how our DNA works, scientists need data from a lot of people. This data can come from reading parts or the whole genome of a person.

The Human Genome Project, completed between 1990 and 2003, was a major step in mapping the human genome. Since then, technology has greatly improved, allowing us to sequence DNA much faster and more efficiently, creating vast amounts of genetic data.

Genome sequencing leads to better cancer treatments



Cancer treatment has traditionally been based on where the cancer is found in the body – such as breast cancer or lung cancer. Genomics changes that approach by focusing on the genetic changes that cause cancer in the first place.

Looking at the whole genome of a cancer cell allows doctors to better understand the mutations driving the cancer and choose the most effective treatment. Understanding the genetic code of cancer cells can lead to the development of drugs that can impede the cancer cells but not normal cells. It can also inhibit the enzymes that trigger cancer cell growth and halt the molecular signalling pathways that are in overdrive in cancer cells.

Currently, patients with certain mutations in lung cancer can be treated with targeted therapies that focus on the genetic changes within the cancer. Predicting and preventing diseases using polygenic risk scores


Genomics has a huge potential to predict disease. Polygenic risk scores are developed using large-scale genomics studies. They use genetic information to estimate a person’s risk of developing common diseases like heart disease, diabetes and even some cancers. Polygenic risk scores are already being trialled as an approach. These scores incorporate many small genetic changes, each contributing a little bit to the risk of a disease.

Someone with a high-risk score for heart disease may be advised to take steps to lower their risk, like adopting a healthier lifestyle or getting regular checkups. This type of personalised medicine could save lives by catching diseases early.

Genomics in action: gene therapy for genetic diseases


One of the most exciting advances in medicine is gene therapy, a treatment that changes a person’s DNA to cure or treat diseases caused by genetic mutations.

For example, gene therapy has shown promise in treating sickle cell disease, a serious inherited blood disorder. It’s caused by a mutation in the gene that helps make haemoglobin, the protein in red blood cells that carries oxygen. This mutation causes haemoglobin to stick together, forming sickle-shaped cells that can block blood flow and cause pain.

Around 100 million people worldwide carry the sickle cell trait, but the disease only occurs if both parents pass it on. In parts of Africa where the disease is common, up to 20% of people may be affected. Gene therapy can fix the faulty gene in a patient’s cells, leading to huge improvements in health. In some cases, patients have even been completely cured. This same approach could also be used to treat other genetic disorders, like cystic fibrosis or Duchenne muscular dystrophy, offering hope for new treatments.

Our improved understanding of the genome and its role in health and disease makes treatments like gene therapy possible. This is one of the many potential applications of genomics beyond prevention and diagnosis of disease.

Healthcare, Medical research, Public health, Patient care, Clinical trials, Telemedicine, Health technology, Preventive medicine, Medical innovation, Disease management, Digital health, Healthcare policy, Medical diagnostics, Precision medicine, Health informatics, Biomedical engineering, Chronic disease, Emergency medicine, Global health, Mental health

#Healthcare #MedicalResearch #PublicHealth #PatientCare #ClinicalTrials #Telemedicine #HealthTech #PreventiveMedicine #MedicalInnovation #DiseaseManagement #DigitalHealth #HealthcarePolicy #MedicalDiagnostics #PrecisionMedicine #HealthInformatics #BiomedicalEngineering #ChronicDisease #EmergencyMedicine #GlobalHealth #MentalHealth

March 21, 2025

Human Evolution

Genetic study reveals hidden chapter in human evolution

Modern humans descended from not one, but at least two ancestral populations that drifted apart and later reconnected, long before modern humans spread across the globe.

Using advanced analysis based on full genome sequences, researchers from the University of Cambridge have found evidence that modern humans are the result of a genetic mixing event between two ancient populations that diverged around 1.5 million years ago. About 300,000 years ago, these groups came back together, with one group contributing 80% of the genetic makeup of modern humans and the other contributing 20%.

For the last two decades, the prevailing view in human evolutionary genetics has been that Homo sapiens first appeared in Africa around 200,000 to 300,000 years ago, and descended from a single lineage. However, these latest results, reported in the journal Nature Genetics, suggest a more complex story.

"The question of where we come from is one that has fascinated humans for centuries," said first author Dr. Trevor Cousins from Cambridge's Department of Genetics. "For a long time, it's been assumed that we evolved from a single continuous ancestral lineage, but the exact details of our origins are uncertain."

"Our research shows clear signs that our evolutionary origins are more complex, involving different groups that developed separately for more than a million years, then came back to form the modern human species," said co-author Professor Richard Durbin, also from the Department of Genetics.

While earlier research has already shown that Neanderthals and Denisovans—two now-extinct human relatives—interbred with Homo sapiens around 50,000 years ago, this new research suggests that long before those interactions—around 300,000 years ago—a much more substantial genetic mixing took place.

Unlike Neanderthal DNA, which makes up roughly 2% of the genome of non-African modern humans, this ancient mixing event contributed as much as 10 times that amount and is found in all modern humans.

The team's method relied on analyzing modern human DNA, rather than extracting genetic material from ancient bones, and enabled them to infer the presence of ancestral populations that may have otherwise left no physical trace. The data used in the study are from the 1000 Genomes Project, a global initiative that sequenced DNA from populations across Africa, Asia, Europe, and the Americas.

The team developed a computational algorithm called cobraa that models how ancient human populations split apart and later merged back together. They tested the algorithm using simulated data and applied it to real human genetic data from the 1000 Genomes Project.

While the researchers were able to identify these two ancestral populations, they also identified some striking changes that happened after the two populations initially broke apart.

"Immediately after the two ancestral populations split, we see a severe bottleneck in one of them—suggesting it shrank to a very small size before slowly growing over a period of one million years," said co-author Professor Aylwyn Scally, also from the Department of Genetics.

"This population would later contribute about 80% of the genetic material of modern humans, and also seems to have been the ancestral population from which Neanderthals and Denisovans diverged."

"However, some of the genes from the population which contributed a minority of our genetic material, particularly those related to brain function and neural processing, may have played a crucial role in human evolution," said Cousins.

The study also found that genes inherited from the second population were often located away from regions of the genome linked to gene functions, suggesting that they may have been less compatible with the majority genetic background. This hints at a process known as purifying selection, where natural selection removes harmful mutations over time.

Beyond human ancestry, the researchers say their method could help to transform how scientists study the evolution of other species. In addition to their analysis of human evolutionary history, they applied the cobraa model to genetic data from bats, dolphins, chimpanzees, and gorillas, finding evidence of ancestral population structure in some but not all of these.

"What's becoming clear is that the idea of species evolving in clean, distinct lineages is too simplistic," said Cousins. "Interbreeding and genetic exchange have likely played a major role in the emergence of new species repeatedly across the animal kingdom."

So who were our mysterious human ancestors? Fossil evidence suggests that species such as Homo erectus and Homo heidelbergensis lived both in Africa and other regions during this period, making them potential candidates for these ancestral populations, although more research (and perhaps more evidence) will be needed to identify which genetic ancestors corresponded to which fossil group.

Looking ahead, the team hopes to refine their model to account for more gradual genetic exchanges between populations, rather than sharp splits and reunions. They also plan to explore how their findings relate to other discoveries in anthropology, such as fossil evidence from Africa that suggests early humans may have been far more diverse than previously thought.

"The fact that we can reconstruct events from hundreds of thousands or millions of years ago just by looking at DNA today is astonishing," said Scally. "And it tells us that our history is far richer and more complex than we imagined."

Human evolution, natural selection, hominins, bipedalism, genetic adaptation, primates, Neanderthals, Homo sapiens, fossil evidence, paleoanthropology, evolutionary biology, brain expansion, cultural evolution, early humans, migration patterns, tool use, DNA analysis, survival strategies, anthropogenesis, extinct species

#HumanEvolution, #NaturalSelection, #Hominins, #Bipedalism, #GeneticAdaptation, #Primates, #Neanderthals, #HomoSapiens, #FossilEvidence, #Paleoanthropology, #EvolutionaryBiology, #BrainExpansion, #CulturalEvolution, #EarlyHumans, #MigrationPatterns, #ToolUse, #DNAAnalysis, #SurvivalStrategies, #Anthropogenesis, #ExtinctSpecies


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 20, 2025

SpeciCare Revolutionizes Gene Mapping

SpeciCare Revolutionizes Cancer Treatment with Tumor Cryopreservation and Gene Mapping


SpeciCare cryopreserves tumor tissue, enabling expanded therapy testing and empowering patients with personalized, future-ready treatment opportunities.

GAINESVILLE, GA, UNITED STATES, March 17, 2025 /EINPresswire.com/ -- SpeciCare, a pioneering healthcare company, is transforming cancer treatment by offering patients the ability to cryopreserve their tumor tissue for advanced genomic assays and more specific personalized therapies. Founded by a group of oncology specialists and advanced clinical researchers, SpeciCare aims to move beyond traditionally mass-administered cancer treatments to provide more effective individualized cancer care.

For decades, cancer treatment has relied on outdated tumor storage methods that provide limited views of the affected tissue—like trying to solve a city’s traffic crisis using a single aerial snapshot. But what if researchers had a live traffic feed instead? That’s what cryopreserving tumor tissue offers—an evolving, real-time window into cancer’s behavior, which is currently the missing component in bringing precision oncology care to the individual cancer patient.

By cryopreserving live tumor tissue, SpeciCare enables comprehensive genomic assays, which is not possible with the current FFPE method that destroys testable tissue. This necessary modification in the way that tissue is preserved and stored facilitates the development of tailored treatment plans for each patient. This individualized approach increases the efficacy of therapies and minimizes unnecessary side effects, offering patients a more targeted and effective treatment journey.

Access to their own cryopreserved tissue with Specicare allows patients to participate in multiple clinical trials simultaneously, without the need for additional surgeries or invasive procedures. This accessibility not only broadens treatment options but also accelerates the discovery of new therapies, benefiting not only the individual patient, but the broader cancer community as well.

The rise in cord blood banking popularity has highlighted the benefits of preserving personal biologics for future medical use. Similarly, tumor cryopreservation offers patients the opportunity to safeguard their unique cancer profile, ensuring access to cutting-edge treatments as they become available without added invasive procedures to acquire new tissue.

The time is right for the adoption of this much-improved method of tumor tissue management with the explosive addition of Artificial Intelligence (AI) to the healthcare space and specifically in the area of genomic assays. The union of Specicare’s access to the consented patient, the electronic medical record and the pristine tumor specimen is central to bringing AI successfully into the oncologic treatment arena.

The window between the initial suspicion of cancer and the biopsy is often narrow, making early intervention crucial. SpeciCare emphasizes the importance of involving preservation services as soon as cancer is suspected, ensuring that collection kits are available to surgeons before the biopsy. SpeciCare is committed to making advanced cancer treatments accessible to the individual patient and his or her family, with initial costs under $500. This affordability ensures that more patients can benefit from personalized therapies without financial strain.

Dr. Ken Dixon founded SpeciCare out of a desire to offer more to his patients. Frustrated with the limitations of traditional treatments, he envisioned a future where patients have control over their tumor tissue, unlocking new avenues for personalized care and improved outcomes.

Gene mapping, genetic markers, genome sequencing, linkage analysis, association mapping, quantitative trait loci (QTL), SNP genotyping, whole genome sequencing, genetic variation, gene localization, recombination frequency, chromosomal mapping, DNA sequencing, functional genomics, positional cloning, genetic linkage, genetic mapping techniques, molecular markers, bioinformatics in gene mapping, next-generation sequencing (NGS),

#GeneMapping, #GeneticMarkers, #GenomeSequencing, #LinkageAnalysis, #AssociationMapping, #QTL, #SNPGenotyping, #WholeGenomeSequencing, #GeneticVariation, #GeneLocalization, #RecombinationFrequency, #ChromosomalMapping, #DNASequencing, #FunctionalGenomics, #PositionalCloning, #GeneticLinkage, #MolecularMarkers, #Bioinformatics, #NextGenSequencing, #GenomicsResearch

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 18, 2025

Scientists Solve One of Genomics

Scientists Solve One of Genomics’ Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes


MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes.

Segmental duplications (SDs) are highly similar, duplicated regions of the genome that have posed persistent challenges for genetic analysis. These regions contain hundreds of genes critical to human health—including those implicated in spinal muscular atrophy (SMN1/SMN2), congenital adrenal hyperplasia (CYP21A2), and red-green color blindness (OPN1LW/OPN1MW)—but their high sequence similarity makes accurate mapping and variant detection nearly impossible with short-read sequencing. Paraphase, combined with HiFi sequencing, overcomes these challenges by phasing haplotypes across paralogous gene families, providing a more complete and accurate view of genetic variation. This is enabled by the length and accuracy of reads from HiFi sequencing.

Study Reveals Previously Inaccessible Regions of the Genome


By applying Paraphase to 160 long (>10 kb) segmental duplication regions spanning 316 genes, the researchers revealed new insights into genetic variation across five ancestral populations.

Among the key findings:Newly Identified De Novo Variants in SDs in Parent-Offspring Trios: Analysis of 36 trios uncovered 7 previously undetected de novo single nucleotide variants (SNVs) and 4 de novo gene conversion events, two of which were non-allelic—a level of detail not possible with traditional sequencing approaches.

Copy Number Variability Across Populations: The study profiled the copy number distributions of paralog groups across populations, showing high copy number variability in many gene families in SDs. It also provided a new approach for identifying false duplications in the reference genome.
Gene Conversion Drives Sequence Similarity between Genes and Paralogs: The team identified 23 paralog groups with strikingly low genetic diversity between genes and paralogs, indicating that frequent gene conversion and/or unequal crossing-over may have played a role in preserving highly similar gene copies over time.

“For decades, sequencing technologies have struggled to provide reliable data on paralogous genes—some of the most medically relevant but hardest to analyze regions of the genome,” said Dr. Michael A. Eberle, Vice President of Bioinformatics at PacBio and senior author of the study. “With Paraphase and HiFi sequencing, we now have a scalable way to accurately genotype SD-encoded genes across diverse populations, filling in long-standing gaps in genomic research and improving our ability to identify disease-linked variants.”

The study also highlights how Paraphase can disentangle medically important gene families that have long required specialized, multi-step assays like MLPA and Sanger sequencing. For example, in the CYP21A2/CYP21A1P region—where mutations cause congenital adrenal hyperplasia—the researchers characterized a previously overlooked duplication allele carrying both a functional CYP21A2 copy and a CYP21A2(Q319X) pseudogene copy, which could have led to misclassification in standard tests.

“This study demonstrates that when we use HiFi sequencing we see a much richer and more complex picture of genetic variation,” said Dr. Xiao Chen, lead author of the study and principal scientist at PacBio. “Paraphase enables the precise resolution of genetic regions that have been largely inaccessible until now, providing new opportunities for disease research, population genetics, and potentially even clinical testing.”

“Long-read genome sequencing offers the ability to detect variants that are difficult to identify using other testing methods, particularly in regions with highly similar sequence,” said Dr. Paul Kruszka, MD, FACMG, Chief Medical Officer at GeneDx. “This work may enhance variant detection, resolve complex genomic regions, and provide more answers for patients and families, so we are encouraged by the prospect of the data.”

The full study, “Genome-wide profiling of highly similar paralogous genes using HiFi sequencing,” is now available in Nature Communications.

About PacBio


PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. For more information, please visit www.pacb.com 

Genomics, DNA sequencing, gene expression, epigenetics, CRISPR, genome editing, transcriptomics, proteomics, personalized medicine, bioinformatics, genetic variation, whole genome sequencing, next-generation sequencing, pharmacogenomics, functional genomics, population genetics, evolutionary genomics, structural genomics, metagenomics, synthetic biology

#Genomics #DNASequencing #GeneExpression #Epigenetics #CRISPR #GenomeEditing #Transcriptomics #Proteomics #PersonalizedMedicine #Bioinformatics #GeneticVariation #WGS #NGS #Pharmacogenomics #FunctionalGenomics #PopulationGenetics #EvolutionaryGenomics #StructuralGenomics #Metagenomics #SyntheticBiology


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 17, 2025

Gene Editing in the Liver

Improving Gene Editing in the Liver


Technique shows promise for treating genetic diseases that require correction or replacement of defective genes in the liver.

Advances in genome editing have raised hopes for curing a wide range of disorders caused by single genetic mutations. Hundreds of such conditions could potentially be treated by correcting disease-causing genes in the liver alone.

Cells in the liver can be easily reached by gene editing tools. Early studies that used gene editing to shut down the activity of genes in the liver have shown promise. But many more disorders are caused by defective genes that need to be repaired to restore normal function. A gene editing approach called homology-directed repair can potentially replace parts or all of a defective gene. But this technique requires actively dividing cells to work.

A research team led by Drs. William Lagor from Baylor College of Medicine and Gang Bao from Rice University have been developing a homology-directed repair system called Repair Drive to give genetically edited cells a jumpstart using the liver’s natural growth processes. The system uses small interfering RNA (siRNA) to temporarily shut down an essential gene called Fah in liver cells. This knock-down process can be tailored to last for specific periods of time.

To deliver a healthy version of the gene that needs repair or replacement, the team attaches it to a version of Fah that is resistant to the siRNA inhibition. This repair package is then delivered to liver cells using a modified version of a virus. In theory, this combination would let populations of gene-edited cells grow while removing unedited cells.

In a set of new studies, funded in part by NIH, the researchers tested Repair Drive in several mouse models. Their results were published on February 12, 2025, in Science Translational Medicine.

The researchers observed rapid growth of cells edited with Repair Drive after siRNA administration. The mice showed signs of mild liver damage, as expected. But this damage resolved by 12 weeks after treatment.

To look at long-term safety, the team used Repair Drive to deliver a gene called FIX to adult mice. Defects in FIX cause a type of hemophilia, a bleeding disorder, in people. The team used siRNA to suppress normal Fah for 3 months, then examined the mouse livers after a year.

They found that Repair Drive mice secreted about five times more FIX after a year than they did before gene repair. The amount of FIX produced by the repaired liver cells would be enough to prevent dangerous bleeding events in people with FIX defects. By a year after treatment, the mice had normal-appearing livers and normal Fah activity, or expression.

Notably, Repair Drive did not raise liver cancer rates in the mice. Two mice in each group had small areas of abnormal growth in their livers, which are common for mice of this age, but these did not show cancerous changes.

“Think of a yard full of weeds—that is like a diseased liver. The weeds are cells that don’t express the gene that they should be expressing,” Lagor explains. “Using Repair Drive, we come in and kill off the weeds, or the unhealthy cells. In doing so, we basically create space for fresh new grass plugs (i.e. corrected cells) to grow and make a new lawn. We also spent a lot of effort making sure that the weed killing only happens for a brief period of time, and that the lawn is healthy in the long run.”

More work is needed to test the Repair Drive system in models that have other common liver diseases, such as viral infections or fatty liver disease. The technique also needs to be tested for safety in larger animal models.

Liver disease, hepatology, cirrhosis, fibrosis, liver function, fatty liver, hepatitis, liver detox, bile production, liver enzymes, hepatocytes, liver cancer, transplantation, oxidative stress, cholestasis, NAFLD, ALD, viral hepatitis, hepatic metabolism, liver regeneration,

#LiverHealth, #Hepatology, #Cirrhosis, #FattyLiver, #Hepatitis, #LiverFunction, #LiverDetox, #LiverCare, #LiverSupport, #LiverEnzymes, #LiverDisease, #LiverCancer, #LiverTransplant, #NAFLD, #ALD, #LiverHealing, #LiverRegeneration, #LiverWellness, #BileProduction, #OxidativeStress


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 15, 2025

Fertility Crash

The fertility crash comes down to what men are doing-or not doing-Nobel laureate says



Falling fertility rates around the world have alarmed governments, tech execs like Elon Musk, and economists. While numerous policies and financial incentives have been employed, few have been proven to reliably boost fertility. But a new study from Nobel Prize–winning economist Claudia Goldin points to the extra hours women spend on child-rearing and household chores compared with men.

She found that was a major difference between countries with low fertility and those with even lower rates, or the “lowest-low” nations. In Sweden, for example, women spend just 0.8 hours more than men each day around the house, and the country’s fertility rate is 1.7 kids per family. And in Denmark, where women work 0.9 hours extra, the fertility rate is also 1.7.

To be sure, both rates are below the so-called replacement rate of 2.1 kids per family, which is needed for a country to maintain a stable population. But they exceed countries with even lower fertility. In South Korea, where the fertility rate is 0.9 kids, women put in 2.8 hours more than men on the home and family each day. And in Italy, where the fertility rate is 1.3, women spend 2.9 extra hours.

The U.S., meanwhile, has a Scandinavian-like fertility rate of 1.7, even though women do 1.8 more hours of work at home. In an interview with Washington Post columnist Heather Long, Goldin said men’s assumptions about what other fathers are doing are important.

“It won’t change unless the guy’s expectations about what he’s ‘supposed to do’ changes,” she explained. “There’s some evidence that individual men believe in couple equity more than they act on it, because they believe other people don’t feel this way.”

As economies developed rapidly or experienced steep postwar recoveries, women entered the workforce in droves, clashing with some cultural norms. “When you have rapid growth, then you don’t give generations enough time to get used to modernity. You thrust them into modernity,” Goldin said. While her paper doesn’t advocate for a particular policy solution, she told the Post that U.S. lawmakers could provide government-subsidized childcare, saying that’s more critical than parental leave.

The study comes as other data point to the crushing burden of caregiving. In Care.com’s latest Cost of Care report, the online marketplace for caregiving services found that 90% of parents lost sleep; 80% cried (with the number rising to 90% for mothers); 85% sacrificed other life goals; 73% lashed out at loved ones; 71% suffered health issues; and 29% considered suicide or self-harm.

Meanwhile, a recent study from the McKinsey Global Institute said much of the world is facing a “youth deficit” as people have fewer children, setting up top economies for population collapse.

Some of those economies are on track to see 20% to 50% population declines by 2100, requiring big changes in how societies and governments operate. If these demographic trends continue, younger people will endure slower economic growth while supporting bigger cohorts of retirees, eroding the historical flows of generational wealth, the study warned. “The current calculus of economies cannot support existing income and retirement norms—something must give,” it said.

fertility, reproductive health, infertility, pregnancy, IVF, fertility treatment, fertility preservation, egg freezing, sperm health, hormonal balance, ovulation, embryo transfer, assisted reproduction, reproductive medicine, male fertility, female fertility, fertility awareness, natural conception, fertility diet, fertility clinics

#fertility, #reproductivehealth, #infertility, #pregnancy, #IVF, #fertilitytreatment, #fertilitypreservation, #eggfreezing, #spermhealth, #hormonalbalance, #ovulation, #embryotransfer, #assistedreproduction, #reproductivemedicine, #malefertility, #femalefertility, #fertilityawareness, #naturalconception, #fertilitydiet, #fertilityclinics


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 14, 2025

Sexual reproduction

Sexual reproduction in plants under high temperature and drought stress


Climate-change-induced extreme heat and drought increasingly threaten plant growth and development, with a particularly significant impact on sexual reproduction. Heat and drought stress can disrupt key stages of plant sexual reproduction, including flowering time, gametophyte development, pollination, and seed formation, leading to infertility and substantial yield reductions in crops.

This review systematically summarizes the latest research on the effects of heat and drought stress on various stages of plant sexual reproduction and proposes specific strategies to mitigate the agricultural hazards posed by these stresses.

By providing an in-depth analysis of the underlying mechanisms and regulatory networks, this review offers a theoretical basis for advancing fundamental research and optimizing agricultural practices to address the severe challenges climate change presents to agriculture.

Sexual reproduction, fertilization, gametes, sperm, egg, meiosis, genetic variation, offspring, zygote, chromosomes, DNA recombination, ovum, testis, ovary, mitosis, reproductive system, embryo, heredity, biodiversity, species diversity

#SexualReproduction, #Fertilization, #Gametes, #Sperm, #Egg, #Meiosis, #GeneticVariation, #Offspring, #Zygote, #Chromosomes, #DNARecombination, #Ovum, #Testis, #Ovary, #Mitosis, #ReproductiveSystem, #Embryo, #Heredity, #Biodiversity, #SpeciesDiversity


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 13, 2025

Coronary Artery Disease

Machine learning analysis of integrated ABP and PPG signals towards early detection of coronary artery disease


Every year, Coronary Artery Disease (CAD) claims lives of over a million people. CAD occurs when the coronary arteries, responsible for supplying oxygenated blood to the heart, get occluded due to plaque deposits on their inner walls. The most critical fact about this disease is that it develops gradually over the years and by the time symptomatic changes such as angina or shortness of breath appear, the disease has already become severe. The overall aim of the proposed work is to detect CAD efficiently in its early stage while utilizing (radial) arterial blood pressure (ABP) along with photoplethysmogram (PPG) signals so that necessary clinical measures may be taken timely.

To achieve this objective, firstly, ABP and PPG data of 73 CAD and 64 non-CAD (not suffering from any cardiac condition) subjects have been collected from MIMIC-II waveform database with matched subset. Secondly, the collected data is pre-processed using band pass filters having bandwidths of 2.5 to 16 Hz and 1.5 to 16 Hz for ABP and PPG respectively. Thirdly, nineteen features have been extracted from each of the two signals; some of the key features include mean of pulse duration, mean of rising slope and ratio of low frequency to high frequency. Finally, extensive analysis on CAD and non-CAD classification is carried out on the basis of extracted features while employing state-of-the-art classifiers such as support vector machines (SVM), K-nearest neighbors (KNN) and neural networks(NN).

The numerical experiments have led to the interpretation that neural network outperforms other classifiers, claiming an accuracy of about 90%. Moreover, accuracy of the proposed approach is found to be better than the state-of-the-art works reported in literature where one of or combinations of cardiovascular signals, namely, electrocardiogram (ECG), phonocardiogram (PCG) and photoplethysmogram (PPG) have been utilized for the CAD detection.

The global mortality rate due to cardiovascular diseases (CVDs) cause a major concern, approximately 17.9 million deaths in 2019 is being attributed to CVDs. Coronary artery disease is one of the major CVDs; in this pathological condition, the coronary arteries, responsible for supplying oxygenated blood to the heart, get occluded due to plaque deposits on their inner walls. This may further lead to symptoms such as chest pain, shortness of breath, heart attack in the advanced stage of disease development.

The risk factors include high blood pressure, high cholesterols, diabetes, smoking, obesity and a family history of heart disease. Treatment options for the said condition range from lifestyle changes, medication to surgery. It may be noted that once the disease has become severe, it requires clinical intervention, else, it may prove to be fatal. While coronary catheterization is a gold standard for diagnosing CAD, it is an invasive and expensive procedure conducted by skilled cardiologists.

A comparison can demonstrate the effectiveness of our proposed method over other techniques used. Firstly, validation using external datasets from different institutions or equipment was not conducted. Secondly, the proposed method could not be compared with previous methods within the same analytical environment. Additionally, in this study we have extracted the features manually further the use of deep neural networks for classification on CAD can be implemented.

For future work, enhancements can focus on improving the generalization of the dataset and incorporating deep learning methodologies. Additionally, a more comprehensive analysis of other potential features could be explored to further refine the model’s performance.

Coronary heart disease, atherosclerosis, cardiovascular disease, heart attack, myocardial infarction, angina, ischemia, plaque buildup, cholesterol, hypertension, blood pressure, arterial blockage, heart failure, risk factors, prevention, lifestyle changes, heart health, cardiology, medical treatment, diagnosis

#HeartDisease, #CardiovascularHealth, #HeartAttack, #Atherosclerosis, #Hypertension, #Cholesterol, #BloodPressure, #HeartHealth, #Cardiology, #Prevention, #HealthyLifestyle, #Angina, #Ischemia, #PlaqueBuildup, #MedicalTreatment, #Diagnosis, #RiskFactors, #HeartFailure, #ArterialBlockage


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

March 12, 2025

Gene Therapy

Mutated DNA Restored to Normal in Gene Therapy Advance

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely targeted infusions. Researchers have corrected a disease-causing gene mutation with a single infusion carrying a treatment that precisely targeted the errant gene. This was the first time a mutated gene has been restored to normal.

The small study of nine patients announced Monday by the company Beam Therapeutics of Cambridge, Mass., involved fixing a spelling error involving the four base sequences — G, A, C and T — in DNA. The effect was to change an incorrect DNA letter to the right one. The result was a normal gene that functioned as it should, potentially halting liver and lung damage of patients with a rare disorder.

“This is the beginning of a new era of medicine,” said Dr. Kiran Musunuru, a gene therapy researcher at the University of Pennsylvania’s Perelman School of Medicine.

He added that the method offers the hope of treating other genetic diseases precisely by fixing mutations — an alternative to current gene therapies, which either add new genes to compensate for mutated ones, or slicing DNA to silence genes.

Dr. Musunuru is a co-founder and equity holder of Verve Therapeutics, a gene therapy company, and receives funding from Beam Therapeutics for research, but not for this study.

Dr. Richard P. Lifton, president of Rockefeller University and head of its Laboratory of Human Genetics and Genomics, said the sort of gene editing Beam did, rewriting genes with an infusion, “is a holy grail” that “has the promise for being a one-and-done kind of therapy.”

Dr. Lifton is a director of Roche Pharmaceuticals and its subsidiary Genentech. Despite the study’s small size, he said the results are “a very impressive advance and very promising.”

The study involved patients who have alpha-1 antitrypsin deficiency, or AATD, a genetic disease that affects an estimated 100,000 Americans, mostly of European ancestry. That makes it as common as sickle cell in this country. It is progressive and incurable.

The alpha-1 antitrypsin protein is made in the liver and normally goes to the lungs and protects them from inflammation from inhaled irritants like smoke or dust. But in people with the disease, a single change in a DNA letter in the gene results in a misshapen and nonfunctional protein. The result is often emphysema or chronic obstructive pulmonary disease in unprotected lungs.

But many of the aberrant alpha-1 antitrypsin proteins never get to the lungs and instead build up in patients’ livers, often causing cirrhosis.

The gene editing was simple for patients. They sat in a chair for a couple of hours while lipid nanoparticles, like those used in Covid vaccines, were infused into their blood. The nanoparticles did not hold vaccines, though. Instead, they encased a microscopic gene editor. The lipid casing protected the editor on a journey to the liver.

When the nanoparticles reached the liver, the lipid layer peeled off, releasing the editor — a disabled CRISPR molecule that acted like a GPS for the genome and an enzyme to fix the mutation. The CRISPR molecule crawled along the patient’s DNA until it found the one incorrect letter that needed to be repaired among the three billion DNA letters in the genome. Then the editing enzyme replaced that letter with the correct one.

The study divided the patients into three groups and tested three different doses of the gene editor. Those who got the highest dose made enough normal alpha-1 antitrypsin to be in a range where no more damage should occur. There were no serious side effects, said John Evans, Beam’s chief executive officer.

Beam will now be offering the higher dose to the patients who got the lower doses in the company’s study. Beam will also study the treatment in more patients, and test an even higher dose of its gene editor. “And then we immediately have to think about how we can get this approved,” Mr. Evans said.

Dr. Noel McElvaney, a professor at the Royal College of Surgeons in Ireland and an investigator in the Beam study, said there’s a real need for an effective treatment to halt the damage done by the mutated gene. He said he sees patients in their 30s and 40s with severe emphysema and “really bad liver disease.” And, he said, “by the time we see them there is already a significant amount of damage.”

For those suffering the worst effects of AATD, he said, the new gene therapy is “a major major breakthrough.” “The big pro” of the new treatment, he said, is that “it theoretically cures the liver and lung disease in one go.” Dr. McElvaney added, though, that “like all genetic interventions, we have to follow up for a long time to make sure it’s as good as we think it is.”

But patients now have renewed hope, said Dr. Andrew Wilson, scientific director of the Alpha-1 Foundation, an advocacy group. “We have been dreaming of gene therapy as a treatment for this disease,” he said.

Gene, DNA, genome, genetics, mutation, gene expression, epigenetics, heredity, genomics, gene therapy, CRISPR, transcription, translation, nucleotide, genetic variation, gene regulation, genetic engineering, molecular biology, genetic code, biotechnology

#Gene, #DNA, #Genome, #Genetics, #Mutation, #GeneExpression, #Epigenetics, #Heredity, #Genomics, #GeneTherapy, #CRISPR, #Transcription, #Translation, #Nucleotide, #GeneticVariation, #GeneRegulation, #GeneticEngineering, #MolecularBiology, #GeneticCode, #Biotechnology


International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: contact@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare

Chromosome abnormalities

Chromosome abnormalities found in healthy breast tissue Epithelial cells, which line many body surfaces, can transform into several types of...